The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
Commentary|Articles|April 25, 2025
Oncology Experts Preview Abstracts to Watch at the 2025 AACR Annual Meeting
Author(s)Ashling Wahner
Fact checked by: Chris Ryan
Experts from across oncology specialties highlight research being presented at the 2025 AACR Annual Meeting.
Advertisement
Advertisement
Ahead of the
Related to this article
The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.
The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Check out this October recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.
The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
Advances in endocrine therapy, immunotherapy, and ADCs frame unresolved breast cancer treatment questions ahead of BTG 2026.
Advertisement
Advertisement